Bleakley Financial Group LLC Makes New $681,000 Investment in Prestige Consumer Healthcare Inc. $PBH

Bleakley Financial Group LLC purchased a new stake in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH) during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 10,912 shares of the company’s stock, valued at approximately $681,000.

Several other hedge funds and other institutional investors also recently made changes to their positions in PBH. Alliance Wealth Advisors LLC UT boosted its position in Prestige Consumer Healthcare by 4.5% during the 3rd quarter. Alliance Wealth Advisors LLC UT now owns 12,515 shares of the company’s stock worth $781,000 after buying an additional 538 shares during the period. Wealth Alliance LLC lifted its holdings in shares of Prestige Consumer Healthcare by 22.4% during the third quarter. Wealth Alliance LLC now owns 4,088 shares of the company’s stock worth $255,000 after purchasing an additional 747 shares during the period. King Luther Capital Management Corp acquired a new position in shares of Prestige Consumer Healthcare during the third quarter worth $2,268,000. First National Bank of Omaha bought a new stake in shares of Prestige Consumer Healthcare in the third quarter worth $370,000. Finally, Heartland Advisors Inc. increased its holdings in Prestige Consumer Healthcare by 41.4% in the third quarter. Heartland Advisors Inc. now owns 64,376 shares of the company’s stock valued at $4,017,000 after purchasing an additional 18,851 shares during the period. 99.95% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, VP Jeffrey Zerillo sold 1,000 shares of the company’s stock in a transaction that occurred on Wednesday, February 11th. The stock was sold at an average price of $65.93, for a total transaction of $65,930.00. Following the transaction, the vice president directly owned 41,048 shares of the company’s stock, valued at approximately $2,706,294.64. This represents a 2.38% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last three months, insiders sold 2,000 shares of company stock valued at $125,930. Insiders own 1.40% of the company’s stock.

Prestige Consumer Healthcare Stock Performance

Shares of PBH stock opened at $69.36 on Thursday. The firm has a 50 day moving average of $64.95 and a 200-day moving average of $63.40. The company has a market cap of $3.28 billion, a price-to-earnings ratio of 18.35, a price-to-earnings-growth ratio of 2.16 and a beta of 0.43. The company has a quick ratio of 1.93, a current ratio of 3.11 and a debt-to-equity ratio of 0.58. Prestige Consumer Healthcare Inc. has a 52 week low of $57.25 and a 52 week high of $90.04.

Prestige Consumer Healthcare (NYSE:PBH) last issued its earnings results on Thursday, February 5th. The company reported $1.14 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.16 by ($0.02). Prestige Consumer Healthcare had a return on equity of 12.02% and a net margin of 16.90%.The company had revenue of $283.44 million for the quarter, compared to the consensus estimate of $286.93 million. During the same period in the prior year, the company earned $1.22 earnings per share. The firm’s revenue was down 2.4% compared to the same quarter last year. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.540-4.540 EPS. On average, equities analysts forecast that Prestige Consumer Healthcare Inc. will post 4.5 earnings per share for the current year.

Analysts Set New Price Targets

PBH has been the topic of a number of analyst reports. Weiss Ratings reiterated a “hold (c)” rating on shares of Prestige Consumer Healthcare in a research report on Thursday, January 22nd. Zacks Research raised shares of Prestige Consumer Healthcare from a “strong sell” rating to a “hold” rating in a research report on Monday, November 10th. Jefferies Financial Group lowered their price target on shares of Prestige Consumer Healthcare from $70.00 to $66.00 and set a “hold” rating for the company in a report on Friday, January 30th. Finally, Canaccord Genuity Group reduced their price objective on shares of Prestige Consumer Healthcare from $100.00 to $88.00 and set a “buy” rating on the stock in a research note on Friday, November 7th. Three research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat.com, Prestige Consumer Healthcare presently has an average rating of “Hold” and a consensus target price of $80.60.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).